-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, antibiotics are mainly divided into two types, one is β-lactam antibiotics, such as carbapenems, oxycephalosporins, cephalosporins, penicillins, etc.
; the other is non-β-lactam antibiotics, such as polypeptides, lincomycin, chloramphenicol, and the like macrolides
.
It is understood that because the abuse of antibiotics can easily lead to the adverse consequences of increased bacterial resistance, China has been strengthening the management and control of the use of antibiotics to prevent the abuse of antibiotics
.
For example, the “Notice on Continuously Doing a Good Job in the Management of the Clinical Application of Antimicrobial Drugs” issued by the Health Commission proposes to continuously improve the management level of the clinical application of antimicrobial drugs, further implement the requirements for the adjustment of the antimicrobial drug supply catalogue and record management, and strengthen children, the elderly and the elderly.
For pregnant women to manage the clinical application of antibacterial drugs, the discovery and strict supervision of the management of the clinical application of antibacterial drugs are encouraged
.
This year, the National Health Commission issued the "Notice on Further Strengthening the Management of Antimicrobial Drugs to Contain Drug Resistance", requiring the standardization of drug treatment for infectious diseases caused by pathogenic microorganisms such as bacteria, mycoplasma, chlamydia, rickettsiae, spirochetes, and fungi.
.
The document also clearly stated that the rational use of antimicrobial drugs should be included in the hospital review, public hospital performance assessment, and rational drug use assessment, and the requirements for the assessment weight should be appropriately increased
.
According to the industry, with the successive release of various national policies in recent years, the development of pharmaceutical companies in the antibiotic market is not a small challenge
.
Data show that in recent years, under the implementation of antimicrobial control measures such as the graded management of antibiotics, the scale of China's antibiotics market has grown slowly
.
For example, from 2013 to 2015, China's antibiotic drug market grew from 21.
5 billion US dollars to 23.
3 billion US dollars, with a compound annual growth rate of 1.
02%; in 2018, it reached about 25.
6 billion US dollars, a year-on-year increase of 9.
87%
.
However, there are also data that predict that China's antibiotic industry as a whole will maintain greater demand in the next few years.
The market size of China's antibiotics may reach 186.
3 billion yuan in 2021, and the market size may reach 1945 billion yuan in 2022
.
Analysts pointed out that although my country’s anti-infective drug market has slowed down in recent years in the context of controlling the abuse of antibiotics, the market size of anti-infective drugs as basic drugs is still huge.
.
Especially with the acceleration of population aging, the improvement of people's living standards, and the continuous improvement of China's medical security system, it is expected that the market demand for anti-infective drugs will maintain a steady growth in the future, and it will still occupy an important position in China's pharmaceutical market.
.
Some of these companies are also making efforts in this market
.
For example, Qilu Pharmaceuticals is pleased to mention the first imitation of blockbuster antibiotics recently, that is, its 4 types of generic drugs, Ceftazidime Avibactam Sodium for Injection, have been approved for marketing, which is deemed to have passed the consistency evaluation
.
It is reported that ceftazidime and avibactam sodium for injection (sfutal) is a new type of antibiotic used to treat complicated intra-abdominal infection (cIAI), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), Treatment of infections caused by the following gram-negative bacteria that are sensitive to this product in adult patients with limited treatment options: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Proteus mirabilis, and Pseudomonas aeruginosa
.
Antibiotics are widely used in various fields in our country.
Among them, in clinical medicine, the main role is to control bacterial infections, participate in tumor chemotherapy, and alleviate rejection problems in organ transplantation
.
It is understood that cephalosporins occupy an important position in the antibiotic drug market in China, with a market share accounting for 60% of the total industry; penicillins, accounting for 13%; macrolides and carbapenems, the market shares are respectively It is 7%, 5%
.
However, it is worth noting that on the basis of the country's further strengthening of antimicrobial drug management, antibiotic drugs will gradually be strictly controlled, and the market may face challenges
.
; the other is non-β-lactam antibiotics, such as polypeptides, lincomycin, chloramphenicol, and the like macrolides
.
It is understood that because the abuse of antibiotics can easily lead to the adverse consequences of increased bacterial resistance, China has been strengthening the management and control of the use of antibiotics to prevent the abuse of antibiotics
.
For example, the “Notice on Continuously Doing a Good Job in the Management of the Clinical Application of Antimicrobial Drugs” issued by the Health Commission proposes to continuously improve the management level of the clinical application of antimicrobial drugs, further implement the requirements for the adjustment of the antimicrobial drug supply catalogue and record management, and strengthen children, the elderly and the elderly.
For pregnant women to manage the clinical application of antibacterial drugs, the discovery and strict supervision of the management of the clinical application of antibacterial drugs are encouraged
.
This year, the National Health Commission issued the "Notice on Further Strengthening the Management of Antimicrobial Drugs to Contain Drug Resistance", requiring the standardization of drug treatment for infectious diseases caused by pathogenic microorganisms such as bacteria, mycoplasma, chlamydia, rickettsiae, spirochetes, and fungi.
.
The document also clearly stated that the rational use of antimicrobial drugs should be included in the hospital review, public hospital performance assessment, and rational drug use assessment, and the requirements for the assessment weight should be appropriately increased
.
According to the industry, with the successive release of various national policies in recent years, the development of pharmaceutical companies in the antibiotic market is not a small challenge
.
Data show that in recent years, under the implementation of antimicrobial control measures such as the graded management of antibiotics, the scale of China's antibiotics market has grown slowly
.
For example, from 2013 to 2015, China's antibiotic drug market grew from 21.
5 billion US dollars to 23.
3 billion US dollars, with a compound annual growth rate of 1.
02%; in 2018, it reached about 25.
6 billion US dollars, a year-on-year increase of 9.
87%
.
However, there are also data that predict that China's antibiotic industry as a whole will maintain greater demand in the next few years.
The market size of China's antibiotics may reach 186.
3 billion yuan in 2021, and the market size may reach 1945 billion yuan in 2022
.
Analysts pointed out that although my country’s anti-infective drug market has slowed down in recent years in the context of controlling the abuse of antibiotics, the market size of anti-infective drugs as basic drugs is still huge.
.
Especially with the acceleration of population aging, the improvement of people's living standards, and the continuous improvement of China's medical security system, it is expected that the market demand for anti-infective drugs will maintain a steady growth in the future, and it will still occupy an important position in China's pharmaceutical market.
.
Some of these companies are also making efforts in this market
.
For example, Qilu Pharmaceuticals is pleased to mention the first imitation of blockbuster antibiotics recently, that is, its 4 types of generic drugs, Ceftazidime Avibactam Sodium for Injection, have been approved for marketing, which is deemed to have passed the consistency evaluation
.
It is reported that ceftazidime and avibactam sodium for injection (sfutal) is a new type of antibiotic used to treat complicated intra-abdominal infection (cIAI), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), Treatment of infections caused by the following gram-negative bacteria that are sensitive to this product in adult patients with limited treatment options: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Proteus mirabilis, and Pseudomonas aeruginosa
.
Antibiotics are widely used in various fields in our country.
Among them, in clinical medicine, the main role is to control bacterial infections, participate in tumor chemotherapy, and alleviate rejection problems in organ transplantation
.
It is understood that cephalosporins occupy an important position in the antibiotic drug market in China, with a market share accounting for 60% of the total industry; penicillins, accounting for 13%; macrolides and carbapenems, the market shares are respectively It is 7%, 5%
.
However, it is worth noting that on the basis of the country's further strengthening of antimicrobial drug management, antibiotic drugs will gradually be strictly controlled, and the market may face challenges
.
